Reuters logo
6 months ago
BRIEF-Boehringer Ingelheim - To evaluate Afatinib in combination with PD-1 inhibitor pembrolizumab
February 9, 2017 / 2:08 PM / 6 months ago

BRIEF-Boehringer Ingelheim - To evaluate Afatinib in combination with PD-1 inhibitor pembrolizumab

1 Min Read

Feb 9 (Reuters) - Boehringer Ingelheim :

* Boehringer Ingelheim - afatinib to be evaluated in combination with pd-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of lung

* Boehringer Ingelheim - continues to explore afatinib beyond large lux-lung programme and its current indications Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below